Two young Groningen researchers win NWO Rubicon travel grants
Linda Geerligs and Marcos Guimarães are going to conduct research abroad with the help of the programme of the Netherlands Organisation for Scientific Research (NWO). The Rubicon programme is part of NWO’s plans to give recent postdoc researchers the chance to gain research experience abroad at eminent institutions.
Communication in the brain
Linda Geerligs will be conducting research in the UK for two years, at the Medical Research Council, Cognition and Brain Sciences Unit.
The various areas in the brain must communicate in order to function properly. This project will study how changes in this communication take place during a person’s life course, what causes these changes and how they affect cognitive functioning, particularly in older people.
New electronics, one layer at a time
Marcos Guimarães’s destination is the Kavli Institute for Nanoscience, Cornell University, US, also for two years.
Electronic devices are made smaller and smaller, and we seem to be reaching the limit soon. Researchers therefore aim to use a variety of layered nanomaterials to develop and study new types of components that can be used in future electronic devices based on magnetism.
Source: NWO press release
Last modified: | 13 March 2020 02.19 a.m. |
More news
-
17 July 2025
Veni-grants for eleven UG researchers
The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to eleven researchers of the University of Groningen and the UMCG: Quentin Changeat, Wen Wu, Femke Cnossen, Stacey Copeland, Bart Danon, Gesa Kübek, Hannah Laurens, Adi...
-
14 July 2025
ERC Proof of Concept grant for Kottapalli and Covi
Professors Ajay Kottapalli and Erika Covi have received Proof of Concept grants from the European Research Council (ERC).
-
10 July 2025
Dutch Research Agenda funding for nanomedicine research
Prof Dr Anna Salvati, Dr Christoffer Åberg and Prof Dr Siewert-Jan Marrink have been granted a National Science Agenda (NWA) funding to further develop life-saving drugs based on nanotechnology with the NanoMedNL consortium.